Investors

Upcoming results

We will announce our third quarter 2026 results on Wednesday 28 October.

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

Citi European Healthcare CEO Conference

Access all speeches and presentations

10 June 2026

Luke Miels, Chief Executive Officer, attended the Citi European Healthcare CEO Conference in London on Wednesday, 10 June 2026.

GSK enters agreement to acquire Nuvalent, Inc.

Access all speeches and presentations

09 June 2026

GSK management hosted a webcast for investors and analysts to discuss the agreement to acquire Nuvalent, Inc.

BNP Paribas Exane CEO Conference

Access all speeches and presentations

03 June 2026

Julie Brown, Chief Financial Officer, attended the BNP Paribas Exane CEO Conference in Paris on Wednesday, 3 June 2026.

Jefferies Global Healthcare Conference

Access all speeches and presentations

03 June 2026

Hesham Abdullah, SVP, Global Oncology R&D, participated in the Jefferies Global Healthcare Conference in New York on Wednesday, 3 June 2026.

Review of bepirovirsen Phase III data presented at the European Association for the Study of the Liver (EASL)

Access all speeches and presentations

28 May 2026

Following EASL on 28th May, we hosted a call with Nina Mojas, President, Global Product Strategy, Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation, Melanie Paff, VP, MDL HBV Program and Prof Seng Gee Lim, Director of Hepatology, National University Health System, Singapore, highlighting our data from the B-Well 1 and B-Well 2 phase III pivotal studies.

Shareholder information

GSK dividend

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the Science

Exploring how today's discoveries are shaping tomorrow's health

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

Behind the Science magazine

Investors

Upcoming results

We’re confident in our future

Speeches and presentations

Citi European Healthcare CEO Conference

GSK enters agreement to acquire Nuvalent, Inc.

BNP Paribas Exane CEO Conference

Jefferies Global Healthcare Conference

Review of bepirovirsen Phase III data presented at the European Association for the Study of the Liver (EASL)

Shareholder information

GSK dividend

GSK share price

Share price tool

Exploring how today's discoveries are shaping tomorrow's health

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

You might also like

Investors

Upcoming results

We’re confident in our future

Stock exchange announcements

Quarterly results

Analyst consensus

Financial reports

Speeches and presentations

Citi European Healthcare CEO Conference

GSK enters agreement to acquire Nuvalent, Inc.

BNP Paribas Exane CEO Conference

Jefferies Global Healthcare Conference

Review of bepirovirsen Phase III data presented at the European Association for the Study of the Liver (EASL)

Shareholder information

GSK dividend

Dividend calculators (GBp/USD)

Dividend calendar

GSK share price

Share price tool

Exploring how today's discoveries are shaping tomorrow's health

'I had dreams': How HIV care has evolved across a generation

'Long-acting options are the future to prevent transmission of HIV'

‘It’s always there’: Learning to live with chronic hepatitis B

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

You might also like

Pipeline

Our leading scientists

Governance